T. Rowe Price Associates’s Zenas BioPharma ZBIO Stock Holding History

T. Rowe Price Associates’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.1M	Buy	1,226,928 +869,662	+243%	+$17.3M	﹤0.01%	1020
2026 Q1	$6.99M	Sell	357,266 -11,982	-3%	-$269K	﹤0.01%	1305
2025 Q4	$13.4M	Sell	369,248 -5,050	-1%	-$166K	﹤0.01%	1168
2025 Q3	$8.31M	Sell	374,298 -110,904	-23%	-$1.81M	﹤0.01%	1272
2025 Q2	$4.7M	Sell	485,202 -32,404	-6%	-$316K	﹤0.01%	1289
2025 Q1	$4.09M	Buy	517,606 +6,386	+1%	+$50K	﹤0.01%	1307
2024 Q4	$4.19M	Buy	511,220 +24,366	+5%	+$380K	﹤0.01%	1333
2024 Q3	$8.24M	Buy	+486,854	New	+$8.75M	﹤0.01%	1179

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $242M AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates's ZBIO Position: Q2 2026 in Review

T. Rowe Price Associates increased its Zenas BioPharma (ZBIO) stake by 243% in Q2 2026, buying an estimated $17.3M and bringing the position to 1,226,928 shares worth $31.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1020.

T. Rowe Price Associates first reported a position in ZBIO in Q3 2024 and has held it in 8 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

T. Rowe Price Associates held 1,226,928 shares of Zenas BioPharma worth $31.1M as of Q2 2026.
T. Rowe Price Associates bought 869,662 Zenas BioPharma shares in Q2 2026, an estimated $17.3M.
Zenas BioPharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1020 holding.
T. Rowe Price Associates first reported a position in Zenas BioPharma in Q3 2024 and has held it in 8 quarters since.
144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.